Supriya Lifescience reported an 18.9% year-on-year revenue growth for FY26, reaching ₹827.87 crore. Profit After Tax (PAT) for the year increased to ₹209.12 crore. While revenue showed strong growth, particularly in Q4, margins saw a slight contraction.
Supriya Lifescience Reports Strong FY26 Growth with ₹827.87 Crore Revenue
Revenue for FY26 stood at ₹827.87 crore, a 18.9% increase from FY25. Profit After Tax (PAT) for FY26 was ₹209.12 crore, up 11.3% YoY. Reader Takeaway: Robust revenue growth and expanded operations driven by anesthetics, offset by a slight margin dip. ## What just happened Supriya Lifescience Ltd. announced its financial results for the quarter and year ended March 31, 2026. The company reported a significant 18.9% year-on-year (YoY) increase in revenue for the full fiscal year FY26, reaching ₹827.87 crore compared to ₹696.48 crore in FY25. Fourth-quarter revenue showed even stronger momentum, surging 50.2% YoY to ₹276.53 crore. Profit After Tax (PAT) for FY26 was ₹209.12 crore, an 11.3% rise from ₹187.96 crore in the previous year. Earnings Per Share (EPS) also grew to ₹25.98 from ₹23.35. ## Why this matters This performance indicates Supriya Lifescience's ability to expand its market reach and product demand, particularly in the anesthetic segment which drove 54% of FY26 revenue. The company's increased capacity utilization to 74% and commissioning of new manufacturing lines suggest successful operational scaling. However, investors will be keen to understand the reasons behind the slight contraction in EBITDA and PAT margins, which fell by 1.9 and 1.7 percentage points respectively. ## The backstory Supriya Lifescience is a pharmaceutical company focused on Active Pharmaceutical Ingredients (APIs) and specialty chemicals. The company has been working on expanding its manufacturing capabilities and product portfolio. The Lote facility's 'Module E' ramp-up and the Ambernath facility's new dosage lines are key to its growth strategy. Export revenue constitutes a significant portion (82%) of the company's total revenue, highlighting its international market presence. ## What changes now The company's strategic investments in manufacturing and product development appear to be yielding positive revenue results. The focus now shifts to sustaining this growth trajectory while managing cost efficiencies to improve or maintain current margins. The performance in the anesthetic, cardiovascular, and ADHD segments will be crucial. ## Risks to watch The primary concern for investors is the slight contraction in EBITDA and PAT margins. It will be important to ascertain if this is a temporary factor, such as increased raw material costs or operational expenses during expansion, or indicative of a shift in product mix or pricing power. Continued margin pressure could impact overall profitability despite revenue growth. ## Peer comparison While specific peer data is not provided in the filing, Supriya Lifescience's revenue growth of 18.9% for FY26 is a strong indicator in the pharmaceutical API sector, which often sees fluctuating growth rates based on product cycles and regulatory environments. ## Context metrics (time-bound) - **FY26 Revenue:** ₹827.87 crore (18.9% YoY growth) - **FY26 PAT:** ₹209.12 crore (11.3% YoY growth) - **Q4 FY26 Revenue:** ₹276.53 crore (50.2% YoY growth) - **FY26 EBITDA Margin:** 35.5% (down from 37.4% in FY25) - **FY26 PAT Margin:** 25.3% (down from 27.0% in FY25) - **Capacity Utilization:** 74% in FY26 (up from 70% in FY25) - **Export Revenue Share:** 82% of FY26 revenue ## What to track next Investors should closely monitor the company's commentary on margin performance in future quarters, the impact of new manufacturing lines, and the continued growth momentum in key product segments like anesthetics. The ability to pass on cost increases or optimize product mix will be key indicators.
Get stock alerts instantly on WhatsApp
Quarterly results, bulk deals, concall updates and major announcements delivered in real time.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.
